Development and validation of bexarote by bioanalytical methods using liquid chromatography-tandem mass spectroscopy (LC-MS/MS)
Open Access
- 22 January 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Future Journal of Pharmaceutical Sciences
- Vol. 7 (1), 1-10
- https://doi.org/10.1186/s43094-020-00155-6
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- ApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse ModelsScience, 2012
- Development of a Stability-Indicating RP-HPLC Method for Determination of Rupatadine and its Degradation Products in Solid Oral Dosage FormScientia Pharmaceutica, 2012
- Simultaneous Determination of Atorvastatin and Aspirin in Human Plasma by LC–MS/MS: Its Pharmacokinetic ApplicationScientia Pharmaceutica, 2012
- Development and Validation of Amisulpride in Human Plasma by HPLC Coupled with Tandem Mass Spectrometry and its Application to a Pharmacokinetic StudyScientia Pharmaceutica, 2011
- Bexarotene: a promising anticancer agentCancer Chemotherapy and Pharmacology, 2009
- The optimal use of bexarotene in cutaneous T-cell lymphomaBritish Journal of Dermatology, 2007
- A Proof-of-Principle Clinical Trial of Bexarotene in Patients with Non–Small Cell Lung CancerClinical Cancer Research, 2007
- Multicenter Phase II Study of Oral Bexarotene for Patients With Metastatic Breast CancerJournal of Clinical Oncology, 2003
- Validated liquid chromatographic method for the determination of bexarotene in human plasmaJournal of Chromatography B, 2002
- Retinoid X receptorsThe International Journal of Biochemistry & Cell Biology, 1997